tetano
Editor, Senior Moderator
Viruses. 2015 Dec 25;8(1). pii: E6. doi: 10.3390/v8010006.
[h=1]Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry.[/h] Wu W[SUP]1[/SUP], Li R[SUP]2[/SUP], Li X[SUP]3[/SUP], He J[SUP]4[/SUP], Jiang S[SUP]5,[/SUP][SUP]6[/SUP], Liu S[SUP]7[/SUP], Yang J[SUP]8,[/SUP][SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses (IAVs) cause seasonal pandemics and epidemics with high morbidity and mortality, which calls for effective anti-IAV agents. The glycoprotein hemagglutinin of influenza virus plays a crucial role in the initial stage of virus infection, making it a potential target for anti-influenza therapeutics development. Here we found that quercetin inhibited influenza infection with a wide spectrum of strains, including A/Puerto Rico/8/34 (H1N1), A/FM-1/47/1 (H1N1), and A/Aichi/2/68 (H3N2) with half maximal inhibitory concentration (IC50) of 7.756 ? 1.097, 6.225 ? 0.467, and 2.738 ? 1.931 μg/mL, respectively. Mechanism studies identified that quercetin showed interaction with the HA2 subunit. Moreover, quercetin could inhibit the entry of the H5N1 virus using the pseudovirus-based drug screening system. This study indicates that quercetin showing inhibitory activity in the early stage of influenza infection provides a future therapeutic option to develop effective, safe and affordable natural products for the treatment and prophylaxis of IAV infections.
[h=4]KEYWORDS:[/h] entry inhibitor; hemagglutinin; influenza A virus; quercetin
[h=1]Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry.[/h] Wu W[SUP]1[/SUP], Li R[SUP]2[/SUP], Li X[SUP]3[/SUP], He J[SUP]4[/SUP], Jiang S[SUP]5,[/SUP][SUP]6[/SUP], Liu S[SUP]7[/SUP], Yang J[SUP]8,[/SUP][SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses (IAVs) cause seasonal pandemics and epidemics with high morbidity and mortality, which calls for effective anti-IAV agents. The glycoprotein hemagglutinin of influenza virus plays a crucial role in the initial stage of virus infection, making it a potential target for anti-influenza therapeutics development. Here we found that quercetin inhibited influenza infection with a wide spectrum of strains, including A/Puerto Rico/8/34 (H1N1), A/FM-1/47/1 (H1N1), and A/Aichi/2/68 (H3N2) with half maximal inhibitory concentration (IC50) of 7.756 ? 1.097, 6.225 ? 0.467, and 2.738 ? 1.931 μg/mL, respectively. Mechanism studies identified that quercetin showed interaction with the HA2 subunit. Moreover, quercetin could inhibit the entry of the H5N1 virus using the pseudovirus-based drug screening system. This study indicates that quercetin showing inhibitory activity in the early stage of influenza infection provides a future therapeutic option to develop effective, safe and affordable natural products for the treatment and prophylaxis of IAV infections.
[h=4]KEYWORDS:[/h] entry inhibitor; hemagglutinin; influenza A virus; quercetin